Retracted: Effectiveness of cationic liposome-mediated local delivery of myostatin-targeting small interfering RNAin vivo (Development, Growth & Differentiation, (2014), 56, 3, (223-232), 10.1111/dgd.12123);Effectiveness of cationic liposome-mediated local delivery of myostatin-targeting small interfering RNA in vivo

Development Growth and Differentiation

Volumn 56, Issue 3, 2014, Pages 223-232

  Mori, Hiroyo ^a   Kawai, Nobuhiko ^a   Kinouchi, Nao ^a   Hichijo, Natsuko ^a   Ishida, Tatsuhiro ^a   Kawakami, Emi ^a   Noji, Sumihare ^a   Tanaka, Eiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cationic liposome; Muscular dystrophy; Myostatin; RNA interference; Small interfering RNAs

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; LIPOSOME; MYOD PROTEIN; MYOGENIN; MYOSTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMALL INTERFERING RNA; MSTN PROTEIN, MOUSE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTROMYOGRAPHY; GENE DELIVERY SYSTEM; IN VIVO STUDY; MALE; MASSETER MUSCLE; MOUSE; MUSCLE DEVELOPMENT; MUSCLE FIBRIL; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; DRUG EFFECTS; EVALUATION STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; DNA PRIMERS; ELECTROMYOGRAPHY; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER TECHNIQUES; LIPOSOMES; MASSETER MUSCLE; MICE; MICE, INBRED MDX; MYOSTATIN; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84898056795     PISSN: 00121592     EISSN: 1440169X     Source Type: Journal    
DOI: 10.1111/dgd.12583     Document Type: Erratum

References (44)

1. Akhtar, S. & Benter, I. 2007. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182.
2. Banker, B. Q. & Engel, A. G. 2004. Basic reactions of muscle. Myology 1, 691-747.
3. Bartlett, G. R. 1959. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 234, 469-471.
4. Barichello, J. M., Kizuki, S., Tagami, T., Soares, L. A. L., Ishida, T., Kikuchi, H. & Kiwada, H. 2012. Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. Int. J. Pharm. 430, 359-365.
5. Behlke, M. A. 2006. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670.
6. Bottinelli, R., Canepari, M., Pellegrino, M. A. & Reggiani, C. 1996. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. J. Physiol. 495, 573-586.
7. Eckardt, L. & Harzer, W. 1996. Facial structure and functional findings in patients with progressive muscular dystrophy (Duchenne). Am. J. Orthod. Dentofacial Orthop. 110, 185-190.
8. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. & Tuschl, T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
9. Emery, A. E. H. 1993. Duchenne Muscular Dystrophy. Oxford Monographs on Medical Genetics. Oxford Univ. Press, Oxford.
10. Ervasti, J. M. & Campbell, K. P. 1993. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809-823.
11. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. & Mello, C. C. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
12. Kawai, N., Tanaka, E., Langenbach, G. E., van Wessel, T., Brugman, P., Sano, R., van Eijden, T. M. & Tanne, K. 2007. Daily jaw muscle activity in freely moving rats measured with radio-telemetry. Eur. J. Oral Sci. 115, 15-20.
13. Kawai, N., Tanaka, E., Langenbach, G. E., van Wessel, T., Sano, R., van Eijden, T. M. & Tanne, K. 2008. Jaw muscle activity changes after the induction of osteoarthrosis in the temporomandibular joint by mechanical loading. J. Orofac. Pain 22, 153-162.
14. Kawai, N., Sano, R., Korfage, J. A., Nakamura, S., Kinouchi, N., Kawakami, E., Tanne, K., Langenbach, G. E. & Tanaka, E. 2010. Adaptation of rat jaw muscle fibers in postnatal development with a different food consistency: an immnohistochemical and EMG study. J. Anat. 216, 717-723.
15. Kawakami, E., Kinouchi, N., Adachi, T., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanaka, E. & Noji, S. 2011. Atelocollagen-mediated systemic applications of myostatin-targeting siRNA improve the muscular atrophy of caveolin-3-deficient mice. Dev. Growth Differ. 53, 48-54.
16. Kawakami, E., Kawai, N., Kinouchi, N., Mori, H., Ohsawa, Y., Ishimaru, N., Sunada, Y., Noji, S. & Tanaka, E. 2013. Local administrations of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function. PLoS ONE 8, e64719.
17. Kim, S., Garg, H., Joshi, A. & Manjunath, N. 2009. Strategies for targeted nonviral delivery of siRNAs in vitro. Trends Mol. Med. 15, 491-500.
18. Kinouchi, N., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanimoto, Y., Moriyama, K. & Noji, S. 2008. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther. 15, 1126-1130.
19. Koenig, M., Monaco, A. P. & Kunkel, L. M. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-228.
20. Korfage, J. A., Koolstra, J. H., Langenbach, G. E. & van Eijden, T. M. 2005. Fiber-type composition of the human jaw muscles-(part 1) origin and functional significance of fiber-type diversity. J. Dent. Res. 84, 774-783.
21. Lares, M. R., Rossi, J. J. & Ouellet, D. L. 2011. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28, 570-579.
22. Lee, S. J. & McPherron, A. C. 2001. Regulation of myostatin activity and muscle growth. Proc. Natl Acad. Sci. USA 98, 9306-9311.
23. Lin, J., Arnold, H. B., Della-Fera, M. A., Azain, M. J., Hartzell, D. L. & Baile, C. 2002. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem. Biophys. Res. Commun. 291, 701-706.
24. Maughan, R. J., Watson, J. S. & Weir, J. 1983. Strength and cross-sectional area of human skeletal muscle. J. Physiol. 338, 37-49.
25. McCroskery, S., Thomas, M., Maxwell, L., Sharma, M. & Kambadur, R. 2003. Myostatin negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162, 1135-1147.
26. McFarlane, C., Hennebry, A., Thomas, M., Plummer, E., Ling, N., Sharma, M. & Kambadur, R. 2008. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp. Cell Res. 314, 317-329.
27. McPherron, A. C., Lawler, A. M. & Lee, S. J. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90.
28. Minakuchi, Y., Takeshita, F., Kosaka, N., Sasaki, H., Yamamoto, Y., Kouno, M., Honma, K., Nagahara, S., Hanai, K., Sano, A., Kato, T., Terada, M. & Ochiya, T. 2004. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32, e109.
29. Nishi, M., Yasue, A., Nishimatu, S., Nohno, T., Yamaoka, T., Itakura, M., Moriyama, K., Ohuchi, H. & Noji, S. 2002. A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle. Biochem. Biophys. Res. Commun. 293, 247-251.
30. Morel-Verdebout, C., Botteron, S. & Kiliaridis, S. 2007. Dentofacial characteristics of growing patients with Duchenne muscular dystrophy: a morphological study. Eur. J. Orthod. 29, 500-507.
31. Ochiya, T., Nagahara, S., Sano, A., Itoh, H. & Terada, M. 2001. Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr. Gene Ther. 1, 31-52.
32. Phalon, C., Rao, D. D. & Nemunaitis, J. 2010. Potential use of RNA interference in cancer therapy. Expert Rev. Mol. Med. 12, e26.
33. Sano, R., Tanaka, E., Korfage, J. A., Langenbach, G. E., Kawai, N., van Eijden, T. M. & Tanne, K. 2007. Heterogeneity of fiber characteristics in the rat masseter and digastric muscles. J. Anat. 211, 464-470.
34. Simonds, A. K., Muntoni, F., Heather, S. & Fielding, S. 1998. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53, 949-952.
35. Spagnou, S., Miller, A. & Keller, M. 2004. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43, 13348-13356.
36. Stenzel, K. H., Miyata, T. & Rubin, A. L. 1974. Collagen as a biomaterial. Annu. Rev. Biophys. Bioeng. 3, 231-253.
37. Tagami, T., Uehara, Y., Moriyoshi, N., Ishida, T. & Kiwada, H. 2011. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of siRNA. J. Control. Release 154, 149-154.
38. Tagami, T., Suzuki, T., Matsunaga, M., Nakamura, K., Moriyoshi, N., Ishida, T. & Kiwada, H. 2012. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int. J. Pharm. 422, 280-289.
39. Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., Kato, T., Sano, A. & Ochiya, T. 2005. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182.
40. Takeshita, F. & Ochiya, T. 2006. Therapeutic potential of RNA interference against cancer. Cancer Sci. 97, 689-696.
41. Tiemann, K. & Rossi, J. J. 2009. RNAi-based therapeutics-current status, challenge and prospects. EMBO Mol. Med. 1, 142-151.
42. Uezumi, A., Fukada, S., Yamamoto, N., Takeda, S. & Tsuchida, K. 2010. Mesenchymal progenitors distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat. Cell Biol. 12, 143-152.
43. van Wessel, T., Langenbach, G. E., Korfage, J. A., Brugman, P., Kawai, N., Tanaka, E. & van Eijden, T. M. 2005. Fiber type composition of rabbit jaw muscles is related to their daily activity. Eur. J. Neurosci. 22, 2783-2791.
44. Zhu, X., Hadhazy, M., Wehling, M., Tidball, J. G. & McNally, E. M. 2000. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett. 474, 71-75.